Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) have been assigned a consensus recommendation of “Buy” from the ten research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $79.78.
Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday. They set an “overweight” rating and a $85.00 price target on the stock. Leerink Partners assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, March 3rd. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Finally, Guggenheim boosted their price objective on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th.
Read Our Latest Stock Report on ANIP
ANI Pharmaceuticals Trading Up 1.7 %
Insider Activity at ANI Pharmaceuticals
In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the sale, the chief financial officer now directly owns 154,468 shares in the company, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the transaction, the senior vice president now directly owns 68,624 shares of the company’s stock, valued at $4,131,164.80. This trade represents a 1.44 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,700 shares of company stock valued at $610,201. 12.70% of the stock is owned by company insiders.
Hedge Funds Weigh In On ANI Pharmaceuticals
Several institutional investors have recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of ANI Pharmaceuticals by 41.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,899 shares of the specialty pharmaceutical company’s stock valued at $2,648,000 after acquiring an additional 13,948 shares during the last quarter. Stonepine Capital Management LLC purchased a new stake in ANI Pharmaceuticals during the fourth quarter valued at $1,128,000. Rafferty Asset Management LLC bought a new position in ANI Pharmaceuticals during the fourth quarter valued at $200,000. ProShare Advisors LLC grew its stake in shares of ANI Pharmaceuticals by 29.0% in the 4th quarter. ProShare Advisors LLC now owns 6,532 shares of the specialty pharmaceutical company’s stock worth $361,000 after buying an additional 1,469 shares in the last quarter. Finally, Nomura Holdings Inc. increased its holdings in shares of ANI Pharmaceuticals by 1.5% in the 4th quarter. Nomura Holdings Inc. now owns 213,879 shares of the specialty pharmaceutical company’s stock worth $11,823,000 after buying an additional 3,255 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Recommended Stories
- Five stocks we like better than ANI Pharmaceuticals
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Golden Cross Stocks: Pattern, Examples and Charts
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Insider Trades May Not Tell You What You Think
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.